Cronos Group Inc. Common Share
CRON
Positions held
Your positionsCRON isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Cronos Group is well-positioned in the growing specialty drug manufacturing sector, benefiting from increasing demand for innovative healthcare solutions.
- In Q2 2026, Cronos reported a revenue increase of 17% compared to the previous quarter, reaching $53 million.
- The gross margin improved significantly to 53.7%, up from 42.4% in the prior quarter.
- Despite recent growth, Cronos has faced challenges with profitability, as indicated by a negative operating margin in previous quarters.
- The company reported a net income loss of $73.963 million in 2023, highlighting ongoing financial struggles.
- In 2025, Cronos had an operating margin of -13.3%, reflecting persistent operational inefficiencies.
Fundamentals
| Market cap | $1.19B | Enterprise value | $439.34M | Trailing P/E | 16.95 | Forward P/E | -80.50 |
| PEG | — | Price / book | 1.12 | Beta | 1.20 | Dividend yield | 0.00% |
| Revenue growth | 58.4% | Earnings growth | — | Gross margin | 43.0% | Operating margin | 15.4% |
| Profit margin | 39.1% | ROE | 7.0% | ROA | -0.1% | Debt / equity | 0.00 |
| Current ratio | 16.18 | Free cash flow | $6.11M | Analyst recommendation | strong_buy | Mean target | $2.47 |
| 52w high | $3.61 | 52w low | $2.28 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $53.0M | $45.2M | $44.5M | $36.3M | $33.5M | — |
| Op margin | 14.3% | -3.2% | -14.4% | -13.8% | -13.6% | — |
| Net income | $32.1M | $13.8M | -$1.8M | $26.0M | -$39.7M | — |
| Gross margin | 53.7% | 42.4% | 36.4% | 50.4% | 43.4% | — |
| Gross profit | $28.5M | $19.2M | $16.2M | $18.3M | $14.5M | — |
| Operating income | $7.6M | -$1.5M | -$6.4M | -$5.0M | -$4.6M | — |
- Revenue +17% vs prior quarter ($53M vs $45M).
- Gross margin 53.7% (was 42.4% prior quarter).
- Operating margin expanded to 14.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $147M | $118M | $87.2M | $86.7M | — |
| Op margin | -13.3% | -50.6% | -91.6% | -120.3% | — |
| Net income | -$9.4M | $41.1M | -$74.0M | -$169M | — |
| Gross margin | 42.8% | 21.4% | 13.7% | 17.8% | — |
| Gross profit | $62.8M | $25.2M | $11.9M | $15.4M | — |
| Operating income | -$19.5M | -$59.5M | -$79.9M | -$104M | — |
Headlines — watch
• [WARN · legal] Is Cronos Group (TSX:CRON) A Bargain Following Its Proposed $10 Million Settlement?
• [WARN · legal] Labaton Keller Sucharow LLP Announces a Proposed Settlement in the Cronos U.S. Securities Settlement
News
2026-10-08 · Cronos Group Inc. to Hold 2026 Third Quarter Earnings Conference Call on November 5, 2026
2026-10-05 · Is Cronos Group (TSX:CRON) A Bargain Following Its Proposed $10 Million Settlement?
2026-09-28 · Can Cronos turn production and brand power into a bigger cannabis comeback?
2026-09-28 · Canadian Penny Stocks To Watch In September 2026
2026-09-24 · Cronos Group Investor Day Highlights Cannabis Growth, Cash Flow and Global Ambitions
2026-09-24 · Cronos Hosts 2026 Investor Day
2026-09-23 · Labaton Keller Sucharow LLP Announces a Proposed Settlement in the Cronos U.S. Securities Settlement
2026-09-22 · 3 Canadian Penny Stocks To Watch With Up To 95% Fair Value Discount
2026-09-22 · 2 Cannabis Stocks That Are Quietly Trouncing the Market in 2026
2026-09-15 · Cronos to Host 2026 Investor Day at its Cronos GrowCo Facility in Kingsville, Ontario
2026-09-14 · Cronos Group (CRON) Returns To Profit Amid A Renewed Trade Threat
2026-09-02 · Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Price (daily)
Full chart · RSI · MACD · patterns